Lars Farde Selected Research

N- (3- iodoprop- 2- enyl)- 2- beta- carbomethoxy- 3- (4- methylphenyl)nortropane

2/2012	Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy.
2/2005	Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lars Farde Research Topics

Disease

27	Schizophrenia (Dementia Praecox) 01/2022 - 01/2002
13	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 06/2006
12	Parkinson Disease (Parkinson's Disease) 01/2020 - 10/2004
12	Mental Disorders (Mental Disorder) 01/2018 - 03/2002
6	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 01/2018
6	Major Depressive Disorder (Major Depressive Disorders) 01/2019 - 11/2011
6	Amyloid Plaque 12/2015 - 06/2006
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 04/2008
4	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 09/2009 - 02/2005
3	Neoplasms (Cancer) 12/2021 - 01/2020
2	Brain Neoplasms (Brain Tumor) 01/2021 - 01/2020
2	Cognitive Dysfunction 01/2016 - 09/2014
2	Neuroinflammatory Diseases 12/2015 - 09/2015
2	Anxiety Disorders (Anxiety Disorder) 02/2014 - 11/2013
2	Juvenile Myoclonic Epilepsy 02/2012 - 06/2005
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2002 - 08/2002
1	Synucleinopathies 01/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2021
1	Glioblastoma (Glioblastoma Multiforme) 12/2021
1	Autistic Disorder (Autism) 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2021
1	Epilepsy (Aura) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Type 2 Diabetes Mellitus (MODY) 12/2018
1	Autism Spectrum Disorder 10/2018
1	Antisocial Personality Disorder (Antisocial Personality) 01/2018
1	Necrosis 04/2017
1	Weight Loss (Weight Reduction) 02/2016
1	Obesity 02/2016
1	Gliosis 12/2015
1	Brain Diseases (Brain Disorder) 06/2015
1	Mood Disorders (Mood Disorder) 05/2015
1	Mania (Manias) 11/2013

Drug/Important Bio-Agent (IBA)

18	Pharmaceutical PreparationsIBA 01/2020 - 01/2002
14	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 05/2002
12	Serotonin (5 Hydroxytryptamine)IBA 01/2022 - 03/2002
9	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 05/2002
7	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2019 - 09/2000
7	Amyloid (Amyloid Fibrils)IBA 11/2017 - 11/2009
6	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 09/2021 - 01/2002
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2006
5	FLB 457IBA 09/2021 - 01/2002
4	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2021 - 01/2003
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2015
4	Dopamine Receptors (Dopamine Receptor)IBA 01/2018 - 05/2002
4	5-HT1B Serotonin ReceptorIBA 01/2016 - 07/2008
4	Amyloid beta-PeptidesIBA 09/2015 - 03/2009
4	2- (6- (methylamino)pyridin- 3- yl)- 1,3- benzothiazol- 6- olIBA 09/2015 - 03/2009
3	RacloprideIBA 12/2006 - 02/2005
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 11/2017
2	5-HT1A Serotonin ReceptorIBA 01/2022 - 06/2005
2	osimertinibIBA 01/2021 - 01/2020
2	Monoamine Oxidase (MAO)IBA 12/2020 - 01/2020
2	LigandsIBA 01/2020 - 12/2015
2	Metabotropic Glutamate 5 ReceptorIBA 01/2020 - 01/2018
2	SCH 23390IBA 01/2019 - 05/2002
2	Biological ProductsIBA 01/2018 - 03/2010
2	Neurotransmitter Agents (Neurotransmitter)IBA 11/2015 - 12/2014
2	AZD3241IBA 09/2015 - 06/2015
2	Peroxidase (Myeloperoxidase)IBA 09/2015 - 06/2015
2	Quetiapine Fumarate (Seroquel)FDA Link 11/2013 - 11/2011
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 08/2013 - 09/2012
2	N- (3- iodoprop- 2- enyl)- 2- beta- carbomethoxy- 3- (4- methylphenyl)nortropaneIBA 02/2012 - 02/2005
2	Clozapine (Clozaril)FDA LinkGeneric 11/2011 - 03/2003
2	vinpocetineIBA 11/2002 - 08/2002
1	Protein Kinases (Protein Kinase)IBA 12/2021
1	AZD1390IBA 12/2021
1	AfatinibIBA 01/2021
1	Fluorine-18IBA 12/2020
1	Carbon-11IBA 12/2020
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	fenobamIBA 01/2020
1	AZD9272IBA 01/2020
1	Antidepressive Agents (Antidepressants)IBA 01/2019
1	VortioxetineIBA 01/2019
1	Insulin (Novolin)FDA Link 12/2018
1	Aminobutyrates (Aminobutyric Acid)IBA 10/2018
1	Glutamic Acid (Glutamate)FDA Link 01/2018
1	ApolipoproteinsIBA 11/2017
1	Apolipoproteins E (ApoE)IBA 11/2017
1	Glucose (Dextrose)FDA LinkGeneric 11/2017
1	Tumor Biomarkers (Tumor Markers)IBA 04/2017
1	N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA 02/2016
1	RimonabantIBA 02/2016
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 02/2016
1	N,N- dimethyl- 7- (4- (2- (pyridin- 2- yl)ethyl)piperazin- 1- yl)benzofuran- 2- carboxamideIBA 01/2016
1	benzofuranIBA 01/2016
1	Peptides (Polypeptides)IBA 12/2015
1	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2015
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 12/2014
1	AutoreceptorsIBA 08/2014
1	AminesIBA 06/2014

Therapy/Procedure

2	Therapeutics 08/2014 - 04/2013
1	Drug Therapy (Chemotherapy) 01/2022
1	Radiotherapy 12/2021
1	Aftercare (After-Treatment) 09/2015